

April 23, 2026

**To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001**

Scrip Code: 500 672

Sub.: Reconciliation of Share Capital Audit Report for the quarter and financial year ended March 31, 2026, under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ('The Regulations').

Dear Sir/ Madam,

Pursuant to Regulation 76 of the Regulations, please find enclosed herewith the Reconciliation of Share Capital Audit Report for the quarter and financial year ended March 31, 2026, obtained from **M K Saraf & Associates LLP, Company Secretaries**.

This is for your information and records.

Thank you,

Yours faithfully,

For Novartis India Limited

**Chandni Maru
Company Secretary and Compliance Officer
A60291**

Encl.: as above

M K Saraf & Associates LLP

COMPANY SECRETARIES

LLPIN: ACN-3589 423, Hind Rajasthan Building, 95, Dadasaheb Phalke Road, Dadar Mumbai 400014.

022 24130371 / 022 24153887 mk_saraf@outlook.com +91 9773393877

RECONCILIATION OF SHARE CAPITAL

Under Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018

1	For Quarter Ended	31-03-2026					
2	ISIN	INE234A01025					
3	Face Value	₹ 5/- each					
4	Name of the Company & CIN	Novartis India Limited L24200MH1947PLC006104					
5	Registered Office Address	Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai City MH 400051					
6	Correspondence Address	Same as above					
7	Telephone & Fax No	Tel : +91 22 50243000					
8	Email Address	india.investors@novartis.com					
9	Name of the Stock Exchange where the	Bombay Stock Exchange (BSE)					
		No. of Shares	% of Total Issued Capital				
10	Issued Capital	24690797	100.00				
11	Listed Capital (As per company records)	24690797	100.00				
12	Held in dematerialised form in CDSL	1753473	7.10				
13	Held in dematerialised form in NSDL	22719043	92.02				
14	Physical	218281	0.88				
15	Total No. of Shares (12 + 13 + 14)	24690797	100.00				
16	Reasons for difference if any Between (10&11) (10 & 15) (11 & 15)	NA					
17	Certifying the details of change in share capital during the quarter under consideration as per table below:						
	Particulars *	No of shares	Applied / Not Applied for Listing	Listed on Stock Exchange (Specify Name)	Whether Intimated to CDSL	Whether Intimated to NSDL	In Principle Appl. Pending for SE (Specify Names)
	NIL						
	*Rights, Bonus, Preferential Issues, ESOP's, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to Specify)						
18	Register of Members is updated (Yes/No)	Yes					
19	Reference of previous quarter with regards to excess dematerialized shares if any	NIL					
20	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	Not Applicable					
21	Mention the total no. of requests, if any, Confirmed after 21 days* and the total No. of requests pending beyond 21 days* with the Reasons for delay:						

	Total No. of Demat Requests	No of Req.	No of Shares	Reasons for delay																											
	Confirmed after 21 days	NIL	NIL	NA																											
	Pending for more than 21 days	NIL	NIL	NA																											
22	Name, Telephone & Fax no. of the Compliance Officer of the Company	Ms. Chandni Maru (Membership No. A60291) Company Secretary and Compliance Officer Tel : +91 22 50243000																													
23	Name, Address, Tel, and Fax no. Regn. No. of the Auditor	K.G. SARAF, Designated Partner M K SARAF & ASSOCIATES LLP Mem No. F1596 CP No. 642. 423, Hind Rajasthan Bldg. D.S.P. Road, Dadar (East), Mumbai – 400014. Tel.No.022 24130371/ 022 24153887																													
24	Appointment of Common Agency for Share Registry Work	MUFG INTIME INDIA PVT.LTD C-101, 247 Park, L.B.S. Marg, Vikhroli (W), Mumbai – 400083																													
25	Any other details that the Auditor may like to provide (e.g. BIFR Company), delisting from SE, Company changed its name etc.	NIL																													
<table border="0"> <tr> <td>Place :</td> <td>Mumbai</td> <td>For, M K SARAF & ASSOCIATES LLP</td> </tr> <tr> <td>Date :</td> <td>13.04.2026</td> <td>Company Secretaries</td> </tr> <tr> <td>UDIN :</td> <td>F001596H000080246</td> <td>PR. 6694/2025</td> </tr> <tr> <td></td> <td></td> <td>ICSI UIN : L2025MH018600</td> </tr> <tr> <td></td> <td></td> <td>Kamalax</td> </tr> <tr> <td></td> <td></td> <td>Ganapayya Saraf</td> </tr> <tr> <td></td> <td></td> <td>K.G. SARAF</td> </tr> <tr> <td></td> <td></td> <td>Designated Partner</td> </tr> <tr> <td></td> <td></td> <td>FCS. 1596 CP No. 642</td> </tr> </table>					Place :	Mumbai	For, M K SARAF & ASSOCIATES LLP	Date :	13.04.2026	Company Secretaries	UDIN :	F001596H000080246	PR. 6694/2025			ICSI UIN : L2025MH018600			Kamalax			Ganapayya Saraf			K.G. SARAF			Designated Partner			FCS. 1596 CP No. 642
Place :	Mumbai	For, M K SARAF & ASSOCIATES LLP																													
Date :	13.04.2026	Company Secretaries																													
UDIN :	F001596H000080246	PR. 6694/2025																													
		ICSI UIN : L2025MH018600																													
		Kamalax																													
		Ganapayya Saraf																													
		K.G. SARAF																													
		Designated Partner																													
		FCS. 1596 CP No. 642																													

Digitally signed by Kamalax
Ganapayya Saraf
Date: 2026.04.13 14:19:21
+05'30'